Literature DB >> 22154322

Hemodynamic progression and outcome of asymptomatic aortic stenosis in primary care.

Stefano Nistri1, Pompilio Faggiano, Iacopo Olivotto, Barbara Papesso, Tania Bordonali, Giorgio Vescovo, Livio Dei Cas, Franco Cecchi, Robert O Bonow.   

Abstract

The prognostic relevance of a rapid rate of hemodynamic progression of aortic stenosis (AS) has been predominantly investigated in tertiary centers. We reviewed the clinical and echocardiographic data from 153 asymptomatic patients with AS (age 77 ± 9 years; 65% men), with normal left ventricular function and paired echocardiograms ≥4 months apart (mean 2.9 ± 2.1 years), evaluated in a nonreferral echocardiographic laboratory. The severity of AS was graded by the peak aortic velocity (Vmax) and progression was classified as slow or fast according to a cutoff value of 0.3 m/s increase annually. The end points were all-cause mortality and a composite of all-cause mortality and aortic valve replacement (AVR). At baseline, 135 patients (88%) had mild-to-moderate and 18 (12%) severe AS. Of the 153 patients, 49 (32%) showed fast progression (0.61 ± 0.32 m/s/yr) and 104 (68%) had slow progression (0.10 ± 0.16 m/s/yr). Among the 144 patients (94%) with clinical follow-up data, 40 died and 48 underwent AVR. The mortality rate was greater than that of the general population (p <0.001). On multivariate analysis, the independent predictors of mortality were the yearly change in Vmax (hazard ratio [HR] 13.352 per m/s increase, 95% confidence interval [CI] 5.136 to 34.713, p <0.001) and age (HR 1.122 per year, 95% CI 1.0728 to 1.735, p <0.001). The predictors of the composite end point of death and AVR were the yearly change in Vmax (HR 12.307, 95% CI 6.024 to 25.140, p <0.001) and Vmax on the initial echocardiogram (HR 2.684, 95% CI 1.921 to 3.750, p <0.001). In conclusion, primary care patients with asymptomatic AS are usually elderly and frequently develop rapid hemodynamic progression, which independently predicts, not only AVR, but also overall mortality. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22154322     DOI: 10.1016/j.amjcard.2011.10.035

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Current management of calcific aortic stenosis.

Authors:  Brian R Lindman; Robert O Bonow; Catherine M Otto
Journal:  Circ Res       Date:  2013-07-05       Impact factor: 17.367

2.  ANMCO/SIC/SICI-GISE/SICCH Executive Summary of Consensus Document on Risk Stratification in elderly patients with aortic stenosis before surgery or transcatheter aortic valve replacement.

Authors:  Giovanni Pulignano; Michele Massimo Gulizia; Samuele Baldasseroni; Francesco Bedogni; Giovanni Cioffi; Ciro Indolfi; Francesco Romeo; Adriano Murrone; Francesco Musumeci; Alessandro Parolari; Leonardo Patanè; Paolo Giuseppe Pino; Annalisa Mongiardo; Carmen Spaccarotella; Roberto Di Bartolomeo; Giuseppe Musumeci
Journal:  Eur Heart J Suppl       Date:  2017-05-02       Impact factor: 1.803

Review 3.  Valvulo-Arterial Impedance and Dimensionless Index for Risk Stratifying Patients With Severe Aortic Stenosis.

Authors:  Yogamaya Mantha; Shutaro Futami; Shohei Moriyama; Michinari Hieda
Journal:  Front Cardiovasc Med       Date:  2021-12-02

4.  A novel approach to determine aortic valve area with phase-contrast cardiovascular magnetic resonance.

Authors:  Felix Troger; Ivan Lechner; Martin Reindl; Christina Tiller; Magdalena Holzknecht; Mathias Pamminger; Christian Kremser; Johannes Schwaiger; Sebastian J Reinstadler; Axel Bauer; Bernhard Metzler; Agnes Mayr; Gert Klug
Journal:  J Cardiovasc Magn Reson       Date:  2022-01-06       Impact factor: 5.364

5.  Diabetes Is Associated With Rapid Progression of Aortic Stenosis: A Single-Center Retrospective Cohort Study.

Authors:  Kangning Han; Dongmei Shi; Lixia Yang; Meng Xie; Rongrong Zhong; Zhijian Wang; Fei Gao; Xiaoteng Ma; Yujie Zhou
Journal:  Front Cardiovasc Med       Date:  2022-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.